Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.
BioNTech SE Investigation Details
BioNTech SE shares fell approximately 7.13% after the Company reported that its Phase 2/3 AHEAD-MERIT trial of BNT113 combined with pembrolizumab did not achieve its progression-free survival primary endpoint in HPV16-positive head and neck cancer. The stock decline was clinical-trial-driven, as the trial continues toward its second co-primary endpoint evaluating overall survival. In Form 6-K exhibits filed on August 4, 2026, the Company emphasized an "Advanced diversified pipeline now with 14 ongoing pivotal clinical trials and more than ten novel-novel combinations across major tumor types" while targeting "17+ Late-Stage and Pivotal Trial Readouts Informing Multiple Launch Opportunities." Earlier, during an earnings call on March 10, 2026, Chief Medical Officer Özlem Türeci stated, "Recruitment is ongoing and the Phase III interim analysis is expected in 2026." On August 4, 2026, Chief Medical Officer Özlem Türeci stated, "For BNT113, based on current event accrual projections, we expect a Phase III interim analysis for progression-free survival later this year." The investigation concerns whether BioNTech SE adequately disclosed the clinical trial status and progression-free survival results for BNT113 ahead of the public announcement.
